Benjamin Alexander Mayes

USPTO Granted Patents = 17 (Patent Applications = 14)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 247(Granted Patents)

Company Filing History:

16 out of 100

Idenix Pharmaceuticals, Inc.

patents

4 out of 5,069

Centre National De La Recherche Scientifique

patents

2 out of 2,405

Merck Sharp + Dohme Corp.

patents

4. 2 out of 278

Universitè De Montpellier

patents

5. 2 out of 37

Université Montpellier 2 Sciences Et Techniques

patents

where one patent can have more than one assignee

Years Active: 2010-2020

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10723754 - 2',4′-bridged nucleosides for HCV infection (2020-07-28),

2. 10717758 - D-amino acid compounds for liver disease (2020-07-21),

3. 10683321 - 4'-or nucleosides for the treatment of HCV (2020-06-16),

4. 10513534 - 2'-chloro nucleoside analogs for HCV infection (2019-12-24),

5. 10251903 - Process for making nucleoside phosphoramidate compounds (2019-04-09),

6. 10238680 - D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease (2019-03-26),

7. 10231986 - Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of HCV (2019-03-19),

8. 9339541 - Thiophosphate nucleosides for the treatment of HCV (2016-05-17),

9. 9309275 - 3'-deoxy nucleosides for the treatment of HCV (2016-04-12),

10. 9211300 - 4'-fluoro nucleosides for the treatment of HCV (2015-12-15),

11. 9192621 - Esters and malonates of SATE prodrugs (2015-11-24),

12. 9187515 - 2',4′-fluoro nucleosides for the treatment of HCV (2015-11-17),

13. 9109001 - 3',5′-cyclic phosphoramidate prodrugs for HCV infection (2015-08-18),

14. 8486991 - Enantiomerically pure phosphoindoles as HIV inhibitors (2013-07-16),

15. 8093379 - Macrocyclic serine protease inhibitors (2012-01-10),

Title: The Innovative Contributions of Benjamin Alexander Mayes

Introduction

Benjamin Alexander Mayes is a prominent inventor based in Boston, MA, known for his significant contributions to the field of medicinal chemistry. With a total of 17 patents to his name, Mayes has focused on developing novel compounds for the treatment of viral infections, particularly those caused by the Flaviviridae family, including Hepatitis C virus (HCV).

Latest Patents

Among his latest patents, Mayes has developed 2',4′-bridged nucleosides for HCV infection. These compounds, compositions, and methods are designed to treat Flaviviridae infections effectively. The 2',4′-bridged nucleosides exhibit remarkable efficacy and bioavailability, making them a promising option for HCV treatment in humans. Additionally, he has worked on D-amino acid compounds for liver disease, which also target HCV infections. These compounds can be administered alone or in combination with other antiviral agents, showcasing their versatility in therapeutic applications.

Career Highlights

Mayes has had a distinguished career, working with notable organizations such as Idenix Pharmaceuticals, Inc. and the Centre National De La Recherche Scientifique. His work has significantly advanced the understanding and treatment of viral infections, contributing to the development of effective antiviral therapies.

Collaborations

Throughout his career, Mayes has collaborated with esteemed colleagues, including Adel M Moussa and Alistair James Stewart. These partnerships have fostered innovation and have been instrumental in the success of his research endeavors.

Conclusion

Benjamin Alexander Mayes stands out as a key figure in the field of medicinal chemistry, with his innovative patents paving the way for new treatments for viral infections. His contributions continue to impact the medical community positively, highlighting the importance of research and development in combating diseases.

This text is generated by artificial intelligence and may not be accurate.